We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+12.85%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
Cap. Flow
-$16.5M
Cap. Flow %
-5.78%
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$16.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
ESTA icon
Establishment Labs
ESTA
+$6.8M
5
KURA icon
Kura Oncology
KURA
+$6.54M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.8M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
3
MRK icon
Merck
MRK
+$12.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.75M
5
BLU
BELLUS Health Inc.
BLU
+$6.35M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
2 Miscellaneous 16.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
DELISTED
Apellis Pharmaceuticals
APLS
$911K 0.32%
10,000
-25,000
-71% -$2.16M
AXSM icon
52
Axsome Therapeutics
AXSM
$10.8B
$898K 0.31%
+12,500
New +$922K
MIST icon
53
Milestone Pharmaceuticals
MIST
$149M
$855K 0.3%
300,068
+100,686
+50% +$380K
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$6.15B
$776K 0.27%
30,000
-65,000
-68% -$1.73M
PBYI icon
55
Puma Biotechnology
PBYI
$493M
$714K 0.25%
202,349
+25,000
+14% +$78K
PCVX icon
56
Vaxcyte
PCVX
$9.1B
$695K 0.24%
13,923
-48,300
-78% -$2.29M
JSPR icon
57
Jasper Therapeutics
JSPR
$23.6M
$653K 0.23%
47,695
– –
IMTXW
58
DELISTED
Immatics N.V. Warrants
IMTXW
$633K 0.22%
187,204
– –
TRML
59
DELISTED
Tourmaline Bio
TRML
$608K 0.21%
+20,000
New +$511K
BBIO icon
60
BridgeBio Pharma
BBIO
$14.6B
$604K 0.21%
35,133
-284,867
-89% -$4.29M
VIR icon
61
Vir Biotechnology
VIR
$1.93B
$491K 0.17%
+20,000
New +$502K
NUVB icon
62
Nuvation Bio
NUVB
$2.39B
$450K 0.16%
250,000
– –
NCEL
63
NewcelX Ltd
NCEL
$19.4M
$440K 0.15%
1,000
+140
+16% +$67.4K
CNTX icon
64
Context Therapeutics
CNTX
$33.2M
$428K 0.15%
+267,574
New +$228K
NAMSW icon
65
NewAmsterdam Pharma Warrant
NAMSW
$63.8M
$77.3K 0.03%
37,000
– –
ARAV
66
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$42.3K 0.01%
+33,600
New +$54.5K
RCKTW
67
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
$13.9K ﹤0.01%
75,000
– –
ACRS icon
68
CALL
Aclaris Therapeutics
ACRS
$908M
– –
-129,100
Closed -$1.04M
ARGX icon
69
argenx
ARGX
$64.6B
– –
-10,750
Closed -$4.01M
AZN icon
70
CALL
AstraZeneca
AZN
$252B
– –
-25,000
Closed -$3.47M
BMRN icon
71
BioMarin Pharmaceuticals
BMRN
$12.9B
– –
-25,000
Closed -$2.43M
COGT icon
72
Cogent Biosciences
COGT
$6.03B
– –
-143,064
Closed -$1.54M
ESPR
73
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-350,000
Closed -$557K
ETNB
74
CALL
DELISTED
89bio
ETNB
– –
-36,200
Closed -$551K
ETNB
75
DELISTED
89bio
ETNB
– –
-200,000
Closed -$3.05M
1 2
3
4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $16.5M in Q2 2023, closing 27 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, Affinity Asset Advisors opened a new position in Kyntra Bio worth $2.65M.

  • Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
  • Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
  • Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
  • Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
  • Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.